iBio, Inc. Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2018. Although the request identifies “2017 Q3,” the filing is iBio’s fiscal third-quarter 2018 Form 10-Q, filed May 11, 2018.
Business Context
iBio is a biotechnology company providing product development, manufacturing, and technology-transfer services through its plant-based biopharmaceutical technologies and iBio CDMO facility. It is also developing proprietary candidates for fibrotic diseases, including IBIO-CFB03. The company had not commercialized a vaccine or therapeutic candidate as of March 31, 2018.
Financial Metrics
| Metric | Three Months Ended March 31, 2018 | Three Months Ended March 31, 2017 | Nine Months Ended March 31, 2018 | Nine Months Ended March 31, 2017 |
|---|---|---|---|---|
| Revenue | $78,000 | $37,000 | $353,000 | $247,000 |
| Operating loss | $(3.493) million | $(3.936) million | $(10.281) million | $(10.415) million |
| Consolidated net loss | $(3.963) million | $(4.405) million | $(11.690) million | $(11.809) million |
| Net loss available to iBio stockholders | $(4.026) million | $(3.939) million | $(11.882) million | $(10.229) million |
| Loss per share | $(0.03) | $(0.04) | $(0.12) | $(0.11) |
| Operating expenses | $3.571 million | $3.973 million | $10.634 million | $10.662 million |
The filing does not present a conventional gross margin or cost-of-revenue measure. Given the very low revenue base, the company remained deeply unprofitable on an operating basis.
- Cash: $3.398 million at March 31, 2018, compared with $8.088 million at June 30, 2017.
- Operating cash flow: $(10.105) million for the nine months ended March 31, 2018, versus $(9.398) million in the prior-year period.
- Investing cash flow: $(797,000), including $712,000 of fixed-asset purchases and $85,000 of intangible-asset additions.
- Financing cash flow: $6.214 million, primarily from equity issuance and a $1.050 million contribution from the Eastern affiliate.
- Capital lease obligation: $25.129 million, including $24.935 million classified as long-term. The obligation relates principally to the 34-year sublease of the Bryan, Texas facility and equipment.
- Total assets: $31.034 million; total liabilities: $26.882 million; total equity: $4.152 million.
- Accumulated deficit: $83.810 million at March 31, 2018.
Material Changes Versus Prior Comparable Period
- Quarterly revenue increased $41,000, or approximately 111%, primarily from third-party proof-of-concept, feasibility, and small-scale production contracts.
- Nine-month revenue increased $106,000, or approximately 43%, although the prior-year period included $137,000 of Fiocruz-related revenue that was absent in the current period.
- Quarterly research and development expense declined $170,000 to $966,000, while nine-month research and development expense declined $61,000 to $2.944 million.
- Quarterly general and administrative expense declined $232,000 to $2.605 million; nine-month expense increased $33,000 to $7.690 million.
- Quarterly net loss attributable to iBio stockholders increased from $3.913 million to $3.962 million before preferred dividends, and the nine-month loss increased from $10.203 million to $11.687 million.
- Common shares outstanding increased from 89.119 million at June 30, 2017 to 115.919 million at March 31, 2018, primarily reflecting equity financings and related issuances.
- The company completed a November 2017 public offering of 22.5 million shares for $4.5 million of gross proceeds and sold additional shares to Lincoln Park under a $16 million equity purchase agreement.
Outlook, Risks, Contingencies, and Unusual Items
- Going concern: Management stated that the company’s losses, negative operating cash flow, limited cash resources, and dependence on additional financing raise substantial doubt about its ability to continue as a going concern. Cash on hand was expected to support operations at least through May 31, 2018.
- The company expects continuing significant expenses and operating losses for at least the next year and may require additional equity or other financing. Additional equity financing could substantially dilute existing shareholders.
- On May 2, 2018, the company filed a Form S-1 for a proposed underwritten public offering; the number of shares and offering price had not yet been determined and the offering was subject to SEC effectiveness.
- The company’s 34-year capital lease requires base rent of approximately $2.1 million annually, subject to CPI adjustments, and includes minimum percentage-rent provisions. Future minimum lease payments totaled $67.2 million, including $42.1 million of interest.
- NYSE American notified the company in January 2018 that continued listing depended on a reverse stock split or sustained share-price improvement by July 5, 2018. Stockholders approved authority for a one-for-two to one-for-ten reverse split on April 23, 2018, but the board had not yet determined whether or when to implement it.
- iBio continues litigation against Fraunhofer entities concerning contractual breaches, technology ownership, technology transfer, and related claims. The company stated that the outcome could not be predicted.
- The company owns 99.99% of iBio CDMO following its 2017 exchange transaction with an Eastern affiliate. Eastern beneficially owned approximately 40% of iBio’s common stock as of the filing date, creating significant related-party and ownership concentration considerations.
- The company reported effective disclosure controls and no material changes in internal control over financial reporting during the quarter.
Investor Verification Checklist
- Verify the company’s post-quarter-end financing, including whether the Form S-1 offering became effective, pricing, proceeds, and resulting dilution.
- Verify actual cash runway and subsequent operating cash burn against management’s May 31, 2018 estimate.
- Review whether the board implemented the approved reverse stock split and whether the NYSE American listing deficiency was resolved.
- Assess iBio CDMO’s third-party backlog, customer contracts, utilization, and ability to generate revenue sufficient to offset its facility-related lease costs.
- Review the Fraunhofer litigation, counterclaims, potential damages, and any effects on technology ownership or licensing obligations.
- Monitor related-party transactions with Eastern affiliates and Novici, including capital contributions, lease obligations, interest expense, and ownership concentration.